Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Doxycycline and Pentoxifylline for Mild and Mild-To-Moderate Covid-19

Version 1 : Received: 21 June 2020 / Approved: 24 June 2020 / Online: 24 June 2020 (09:47:14 CEST)

How to cite: Toma, E. Doxycycline and Pentoxifylline for Mild and Mild-To-Moderate Covid-19. Preprints 2020, 2020060293 (doi: 10.20944/preprints202006.0293.v1). Toma, E. Doxycycline and Pentoxifylline for Mild and Mild-To-Moderate Covid-19. Preprints 2020, 2020060293 (doi: 10.20944/preprints202006.0293.v1).

Abstract

We are proposing, for any interested investigator, a randomized open clinical trial for mild and mild-to-moderate Covid-19 comparing a treatment regimen with standard of care, and eventually with another investigational regimen, if ongoing or will be implemented. The patients could be hospitalized or ambulatory but not requiring admission to intensive care units and mechanical ventilation. The proposed therapeutic regimen consists of doxycycline (an antimicrobial having also anti-inflammatory properties, probable antioxidant and possible some antiviral effects), and pentoxifylline, a hemorheological compound used in occlusive arterial diseases but also having proven anti-inflammatory properties. Doxycycline is included in the WHO’s list of essential medicine being an effective, safe, widely available, and inexpensive medication and widely accessible. It will be administered at a dosage of 100 mg orally twice daily for ten days. Pentoxifylline, in clinical use since 1972, and also widely accessible, will be given at a dosage of 400 mg orally, also twice daily, for ten days. The primary outcome measures are: 1) Progression of disease to a severe form requiring intensive care admission and mechanical ventilation; 2) Fatality rates and 3) Time to clinical recovery.This proposal was presented to the National Directors and Core Leads meeting of the Canadian Trials Network (CTN) on May 6, 2020. The interventional trial template suggested by CTN was used for designing the trial.

Subject Areas

Covid-19; SARS-CoV-2; doxycycline; pentoxifylline; treatment; proposal

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.